Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and response. The objective of this retrospective study was to assess off-protocol t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Adv Pract Oncol
Glavni autori: Lemke, Emily A., Shah, Amishi Y., Campbell, Matthew, Tannir, Nizar M.
Format: Artigo
Jezik:Inglês
Izdano: Harborside Press LLC 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7520741/
https://ncbi.nlm.nih.gov/pubmed/33343982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.4.2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items